27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
CHARLOTTESVILLE, VA / ACCESSWIRE / September 26, 2018 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, : %2)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that William Stilley, President and Chief Executive Officer, will be presenting at this year's MicroCap Conference on Monday, October 1st at 9:30 AM, ET, at the Essex House in New York City. Management will also be available for one-on-one meetings with investors. Interested parties can contact Crescendo Communications at (212) 671-1021 or by email at adil@crescendo-ir.com.
REGISTRATION FOR INVESTORS
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
To request free registration, please go to the MicroCap website (www.microcapconf.com), and click the "Registration" button
FOR MORE INFORMATION
Please visit: www.microcapconf.com
Or, contact Ashley Allard at ashley@microcapconf.com
News Compliments of ACCESSWIRE.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug candidate, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Contact:
Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: dwaldman@crescendo-ir.com
SOURCE: Adial Pharmaceuticals, Inc.
View source version on accesswire.com:
https://www.accesswire.com/512828/Adial-Pharmaceuticals-to-Present-at-The-MicroCap-Conference-on-October-1st-in-New-York-City
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.